tbuckley/cabot-search huggingface dataset:
Error in Figure.
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Other Books
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Laboratory Manual of Pharmacology Including Materia Medica, Pharmacopaedics and Pharmacodynamics.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Notices
Journal: Hepatology (1995)

Gallstone and Biliary Disease Center, this postgraduate seminar for surgeons, gastroenterologists, radiologists, and internists will focus on recent major advances in the diagnosis and treatment of gastrointestinal disease.Faculty members distinguished in the field of surgery, gastroenterology, liver disease, and endoscopy will use a series of lectures to present a variety of problematic topics.Ample opportunity will be available for informal discussion and close interaction between faculty and participants.The 5-day program consists of early morning and late afternoon instructional sessions, leaving the middle of the day free for enjoying the area's spectacular recreational activities.
Distinction Awards and Pensions
Journal: BMJ (1970)

205) had evidence of long-acting thyroid stimulator (L.A.T.S.) and also thyroid antibodies.But the immune reaction of the two sisters may not have been the only genetic factor.Sarcoidosis is occasionally found with hyperthyroidism (and with Hashimoto's thyroiditis), and it sometimes occurs familially.' Eight identical twins were indeed reported in the literature.2The past histories of this interesting family may well be of particular relevance.-Iam, etc.,
Erratum
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COUNCIL ON PHYSICAL MEDICINE AND REHABILITATION
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tumor Enhancers: Underestimated Factors in the Epidemiology of Lifestyle-Associated Cancers
Authors: Ernst L. Wynder
Journal: Environmental Health Perspectives (1983)

Model studies in carcinogenesis give ample evidence of synergistic, tumor-promoting and cocarcinogenic effects of environmental agents and dietary factors in regard to the induction and propagation of neoplasms. This presentation examines tumor enhancers deriving from the use of tobacco and alcohol as well as the effects of dietary fat and other food components on endocrinological and gastrointestinal factors that contribute to tumor development in the breast and colon. It is suggested that epidemiologic surveys need to intensify investigations on the interrelationship of tumor enhancers and genotoxic agents in high risk populations and that they need to study especially the dose-response effects of such agents. Experimental studies should focus increasingly on epidemiologic leads that suggest potential enhancers of genotoxic agents and should delineate mechanisms involved in such multistep carcinogenesis processes. This approach would be a prerequisite for chemoprevention. Recommendations for changes of lifestyle habits and practical approaches towards reduction of tumor enhancers in consumer goods and in the environment are additional requirements for appropriate preventive strategies.
Daily Estimates of Soil Ingestion in Children
Authors: Edward J. Stanek, Edward J. Calabrese
Journal: Environmental Health Perspectives (1995)

Soil ingestion estimates play an important role in risk assessment of contaminated sites, and estimates of soil ingestion in children are of special interest. Current estimates of soil ingestion are trace-element specific and vary widely among elements. Although expressed as daily estimates, the actual estimates have been constructed by averaging soil ingestion over a study period of several days. The wide variability has resulted in uncertainty as to which method of estimation of soil ingestion is best. We developed a methodology for calculating a single estimate of soil ingestion for each subject for each day. Because the daily soil ingestion estimate represents the median estimate of eligible daily trace-element-specific soil ingestion estimates for each child, this median estimate is not trace-element specific. Summary estimates for individuals and weeks are calculated using these daily estimates. Using this methodology, the median daily soil ingestion estimate for 64 children participating in the 1989 Amherst soil ingestion study is 13 mg/day or less for 50% of the children and 138 mg/day or less for 95% of the children. Mean soil ingestion estimates (for up to an 8-day period) were 45 mg/day or less for 50% of the children, whereas 95% of the children reported a mean soil ingestion of 208 mg/day or less. Daily soil ingestion estimates were used subsequently to estimate the mean and variance in soil ingestion for each child and to extrapolate a soil ingestion distribution over a year, assuming that soil ingestion followed a log-normal distribution.
A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients
Authors: S. A. Sherwin
Journal: JAMA (1982)

Eighty-one patients with a variety of refractory disseminated malignant neoplasms have been treated in the first multiple fixed-dose phase I trial of recombinant leukocyte A interferon (IFL-rA). Each patient received IFL-rA by intramuscular injection, three times weekly for 28 days. Dosages were escalated in different patients from 1 to 136×10<sup>6</sup>units per injection. The toxic reactions seen with IFL-rA resembled those of nonrecombinant leukocyte interferon and included fever, chills, fatigue, anorexia, myalgia, headache, occasional nausea and vomiting, and dose-dependent reversible leukopenia and hepatic transaminase elevations. The pharmacokinetics of IFL-rA were also comparable with nonrecombinant leukocyte interferon. Objective evidence of antitumor activity was seen in non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease, breast cancer, and melanoma, indicating that IFL-rA, the first genetically engineered biological response modifier available for testing in cancer patients, is biologically active in vivo. (<i>JAMA</i>1982;248:2461-2466)
Booknotes
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
cT3N0 rectal cancer: Potential overtreatment with preoperative chemoradiation (CRT) is warranted
Authors: J. G. Guillem, J. Diaz-Gonzalez, B. Minsky, M. Rodriguez-Bigas, S. Jeong, C. Coco, J. L. Hernandez, V. Valentini, E. Riedel, S. Pucciarelli
Journal: Journal of Clinical Oncology (2006)

3568 Background: Although CRT has emerged as the preferred treatment for T3 and/or lymph node (LN) positive rectal cancer, Sauer et al (NEJM 2004) demonstrated that 18% of patients deemed suitable for preop CRT via endorectal ultrasound (ERUS) were overstaged and therefore received unnecessary preoperative CRT. Since data also suggest that LN negative rectal cancer s/p TME may not need adjuvant therapy, it is reasonable to consider the omission of radiotherapy for the cT3N0 subset. We therefore determined the accuracy of pre-CRT ERUS/MRI staging in order to explore the validity of a non-radiation approach for cT3N0 disease. Methods: 188 ERUS/MRI staged T3N0 rectal cancer patients from 6 insitutions in the US, Europe and Asia received preoperative CRT (5-FU based and 45–52.5 Gy) followed by radical resection. Rates of pathologic complete response (pCR) and mesorectal LN involvement were determined. Results: Tumors were located a median of 5 centimeters from the anal verge. Sphincter-preserving surgery was performed in 135 (81%) patients. Overall pCR was 19%. Median number of LN sampled was 9 (range 0–38). Rate of positive LN was significantly associated with T-stage: pT0: 3%, pT1: 7%, pT2: 20%, pT3–4: 36%(p=0.001). 41 patients (22%) had pathologically positive mesorectal LN. There was no significant difference in rate of positive LN between those staged by ERUS and MRI(25% vs 16%, p=0.19). Conclusions: Accuracy of preoperative ERUS/MRI for identifying mid to distal T3N0 rectal cancer is limited, as 22% will have undetected mesorectal LN involvement despite CRT. Therefore, ERUS/MRI staged T3N0 patients should continue to receive preoperative CRT. Although 19% are overstaged and therefore overtreated, our data suggest that an even larger number would be understaged and require postoperative CRT, which is associated with inferior local control, higher toxicity, and poor functional outcome. No significant financial relationships to disclose.
Epilepsy
Authors: Sharon Parmet
Journal: JAMA (2004)

EpilepsyT he term epilepsy applies to a group of nervous system disorders characterized by recurrent seizures, which are sometimes called convulsions.A seizure occurs when there are abnormal bursts of electrical activity in the brain.Although head trauma, strokes, brain tumors, brain infections, and withdrawal from drugs (including alcohol) can cause seizures, the recurrent seizures of epilepsy are usually idiopathic (of unknown cause).The February 4, 2004, issue of JAMA includes an article about treatments for epilepsy.
Dear Doctor... Regarding Calcium Channel Blockers-Reply
Authors: Bruce M. Psaty
Journal: JAMA (1996)

<h3>In Reply.</h3> —Dr Stryer and colleagues have provided<i>JAMA</i>readers with important background information about the Dear Doctor letter that was sent directly to many US physicians at the time our article was published. We suspect that many clinicians would have interpreted the letter differently if they had known it was solicited by a public relations firm and distributed with drug company sponsorship. Several points in Dr Kaplan's letter deserve comment. First, by saying that "the cases almost certainly had more preexisting coronary risk factors than the controls," Kaplan implies incorrectly that our case-control study was thereby flawed. By definition, patients with myocardial infarction, the cases, will have more risk factors for coronary disease than patients without myocardial infarction, the controls. If our study had been unable to confirm the traditional risk factors for coronary disease in its comparison of cases and controls, the quality and the validity of the
Pneumococcal Disease and HIV Infection
Authors: P. Klenerman
Journal: Annals of Internal Medicine (1993)

Letters1 March 1993Pneumococcal Disease and HIV InfectionP. Klenerman, MD, G. A. Luzzi, MD, and T. E. A. Peto, MDP. Klenerman, MDSearch for more papers by this author, G. A. Luzzi, MDSearch for more papers by this author, and T. E. A. Peto, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-5-199303010-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Janoff and colleagues [1] note that natural resistance to invasive Streptococcus pneumoniae infection may involve humoral factors such as C-reactive protein (CRP). We have investigated serum CRP levels in patients with human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS) who presented with pneumococcal pneumonia.Serum CRP was measured in 21 patients who were hospitalized with fever and respiratory symptoms and signs and in whom S. pneumoniae was isolated from blood or sputum culture. Seven were HIV-1 antibody positive; five fulfilled the Centers for Disease Control criteria for the diagnosis of AIDS, and one had ...References1. Janoff E, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical and immunologic perspectives. Ann Intern Med. 1992; 117:314-24. Google Scholar2. Pepys M. C-reactive protein fifty years on. Lancet. 1981; 1:653-6. Google Scholar3. Mold C, Nakayama S, Holzer TJ, Gewurz H, Duclos TW. C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med. 1981; 154:1703-8. Google Scholar4. Briles DE, Forman C, Horowitz JC, Volanakis JE, Benjamin WH, McDaniel LS, et al. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun. 1989; 57:1457-64. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByClinical efficacy of dirithromycin in patients with bacteremic pneumonia 1 March 1993Volume 118, Issue 5Page: 393-394KeywordsAIDSC-reactive proteinsFeversHIV infectionsInfectious diseasesPneumoniaSigns and symptomsSputumStreptococcal infectionsStreptococcus Issue Published: 1 March 1993 CopyrightCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Coal gas and the brain.
Journal: BMJ (1968)

the lungs include oedema, haemorrhage, and hyaline mem- brane formation.If, however, the affected animals are removed from the highly oxygenated environment and are returned to air they may recover completely.Oxygen therapy is thus a subject to be approached with some caution."2A team of experts should be available to monitor the oxygen content of alveolar air and of the arterial blood in order that dangerously high concentrations may be avoided.Safe administration of oxygen also requires the judgement of the clinician on whether an infant may not be returned to air, at least for a period, without too great a risk of tissue anoxia.
CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex via effects on chromatin remodeling
Authors: Junxin Chen, Gang Liu, Yizheng Wu, Jianjun Ma, Hongfei Wu, Ziang Xie, Shuai Chen, Yute Yang, Shengyu Wang, Panyang Shen, Yifan Fang, Shunwu Fan, Shuying Shen, Xiangqian Fang
Journal: Molecular Cancer (2019)

CircMYO10 is a circular RNA generated by back-splicing of gene MYO10 and is upregulated in osteosarcoma cell lines, but its functional role in osteosarcoma is still unknown. This study aimed to clarify the mechanism of circMYO10 in osteosarcoma.CircMYO10 expression in 10 paired osteosarcoma and chondroma tissues was assessed by quantitative reverse transcription polymerase chain reaction (PCR). The function of circMYO10/miR-370-3p/RUVBL1 axis was assessed regarding two key characteristics: proliferation and endothelial-mesenchymal transition (EMT). Bioinformatics analysis, western blotting, real-time PCR, fluorescence in situ hybridization, immunoprecipitation, RNA pull-down assays, luciferase reporter assays, chromatin immunoprecipitation, and rescue experiments were used to evaluate the mechanism. Stably transfected MG63 cells were injected via tail vein or subcutaneously into nude mice to assess the role of circMYO10 in vivo.CircMYO10 was significantly upregulated, while miR-370-3p was downregulated, in osteosarcoma cell lines and human osteosarcoma samples. Silencing circMYO10 inhibited cell proliferation and EMT in vivo and in vitro. Mechanistic investigations revealed that miR-370-3p targets RUVBL1 directly, and inhibits the interaction between RUVBL1 and β-catenin/LEF1 complex while circMYO10 showed a contrary effect via the inhibition of miR-370-3p. RUVBL1 was found to be complexed with chromatin remodeling and histone-modifying factor TIP60, and lymphoid enhancer factor-1 (LEF1) to promote histone H4K16 acetylation (H4K16Ac) in the vicinity of the promoter region of gene C-myc. Chromatin immunoprecipitation methods showed that miR-370-3p sponge promotes H4K16Ac in the indicated region, which is partially abrogated by RUVBL1 small hairpin RNA (shRNA) while circMYO10 showed a contrary result via the inhibition of miR-370-3p. Either miR-370-3p sponge or ShRUVBL1 attenuated circMYO10-induced phenotypes in osteosarcoma cell lines. MiR-370-3p inhibition abrogated the inhibition of proliferation, EMT of osteosarcoma cells in vitro and in vivo seen upon circMYO10 suppression via Wnt/β-catenin signaling.CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to promote chromatin remodeling and thus enhances the transcriptional activity of β-catenin/LEF1 complex, which indicates that circMYO10 may be a potential therapeutic target for osteosarcoma treatment.
Notifiable diseases.
Authors: D. M. Campbell
Journal: BMJ (1992)

vivors were interviewed about the advice they had been given during and after their admission concerning smoking, diet, and exercise.When appropriate, patients were asked whether the result of serum cholesterol estimation had been discussed with them.Results were analysed with the xI test with Yates's correction.There were 142 eligible admissions (85 men).Thirty patients died before interview, and 17 refused consent or had dementia.The 95 subjects (58 men) interviewed had a median-age of75 (range 70-86) and were interviewed a median of8-6 (range 2 6-14) months after admisson.-Fifteenhad regularly smoked cigarettes.Twelve had been advised to stop and 11 had either done so or cut down considerably.One of the three with whom